Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
A phase 2/3 trial of Carboplatin, Cisplatin and Gemcitabine in bladder & urothelial cancer, run by Daiichi Sankyo, now recruiting.
Overview
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma is a phase 2/3 interventional study registered as NCT07129993 by Daiichi Sankyo, with 630 participants planned, started 2025-09-26 and due to reach its primary completion in 2029-06-01. Interventions recorded: Dato-DXd, Carboplatin, Cisplatin and Gemcitabine.
Similar pages
not linked directly; found by shared links- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Gemcitabine, Cisplatin, AstraZeneca, Carboplatin and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Gemcitabine, Cisplatin, AstraZeneca, Carboplatin and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Gemcitabine, Cisplatin, AstraZeneca, Carboplatin and the tag pipeline.